![Egil Herman Sjursen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Egil Herman Sjursen
Director/Board Member at Cytovation AS
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stein Christian Mohn | M | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Katarina Vaagenes | F | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 14 years |
Tormod Vågenes | M | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 10 years |
Hilde Hukkelberg | F | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Rolf Bjerkvig | M | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Robert Lie Olsen | M | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 13 years |
Harald Jeremiassen | M | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 13 years |
Øyvind Kongstun Arnesen | M | 67 |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Liv Hege Dyrnes | F | 44 |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Raj Airey | M | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Kjell-Inge Arnevig | M | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Lars Prestegarden | M | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | - |
Kjell Bernstrøm | M | - |
Cytovation AS
![]() Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Monica Mjøs Lassen | F | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 9 years |
Petter Slyngstadli | M | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 5 years |
Tony Fimreite | M | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 8 years |
Merethe A. Dyrnes | F | - |
Holberg Fondsforvaltning AS
![]() Holberg Fondsforvaltning AS Investment ManagersFinance Holberg Fondsforvaltning AS (HF) is the wholly-owned fund management subsidiary of Norway-based Holberg Forvaltning AS, a holding company in which the founding partners are significant shareholders. Founded in 2000 by Gunnar J. Torgersen, Monica Mjøs Lassen, Inga Lise Lien Moldestad and Hogne I. Tyssøy, the firm is headquartered in Bergen and manages equity and fixed-income funds for individual and institutional investors. | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
Norway | 17 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Egil Herman Sjursen
- Personal Network